At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 23 enrolled
Drug / intervention
BMS-986231 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Cross-over Phase 2 Study of Continuous 8-Hour Intravenous Infusions of BMS-986231 in Patients With Heart Failure and Impaired Systolic Function Given a Standard Dose of Loop Diuretic
In Brief
A Phase 2 clinical trial evaluating BMS-986231, Furosemide, and 1 other intervention for Cardiac Failure and 3 related conditions. Completed, enrolled 23 participants across 2 sites.
Detailed Summary
The purpose of this study is to investigate continuous 8-hour introductions of BMS-986231 in participants with heart failure and weakened heart function given a standard dose of diuretic.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedNov 2018
Enrollment StartJan 2019
Primary CompletionDec 2019
Study CompletionJan 2020
TodayJul 2026
First PostedNov 5, 2018
Enrollment StartJan 17, 2019
Primary CompletionDec 11, 2019
Study CompletionJan 9, 2020
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 7.7 years ago
Interventions
BMS-986231drug
Intravenous administration
Furosemidedrug
Intravenous administration
Placebodrug
Intravenous administration